NYSE:NNVC
NanoViricides, Inc Stock News
$1.10
-0.0750 (-6.38%)
At Close: Apr 19, 2024
NanoViricides boosts liquidity measures and manufacturing capacity to support clinical trials
10:18am, Thursday, 15'th Feb 2024
NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its lead candidate NV-CoV-2 and enhanced liquidity measures positioni
Pioneering nanomedicine: NanoViricides making big strides fighting viral infections
10:16am, Friday, 02'nd Feb 2024
NanoViricides (NYSE-A:NNVC) has a platform that shows a versatile and effective approach to antiviral therapy, with potential applications that target a broad spectrum of viral diseases. The clinical
NanoViricides highlights lead asset NV-387's potential to revolutionize the treatment of antiviral infections
08:39am, Thursday, 01'st Feb 2024
NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the active ingredient NV-387 shows that they have implicati
NanoViricides' potential to address dozens of diseases highlighted by analysts following trial success
02:56pm, Tuesday, 30'th Jan 2024
NanoViricides (NYSE-A:NNVC) has earned a ‘Buy' rating and a $6.50 price target from EFHutton analysts after the company released positive safety results from its Phase 1a/1b clinical study involving
NanoViricides to Present at the Biotech Showcase in San Fransisco
06:30am, Thursday, 04'th Jan 2024
SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicine
NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug
09:19am, Tuesday, 28'th Nov 2023
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, wi
NanoViricides continues to progress antiviral drug candidate NV-CoV-2 in 3Q
10:24am, Wednesday, 15'th Nov 2023
NanoViricides (NYSE-A:NNVC) said it exited the third quarter with enough cash on hand to progress clinical trials involving its lead drug candidate NV-CoV-2 for SARS-CoV-2 which causes COVID. NV-CoV-2
NanoViricides drug candidate found to be ‘highly effective' for MPox and Smallpox in animal trial
08:45am, Tuesday, 14'th Nov 2023
NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to be “highly effective” for these indications in a
NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus
09:13am, Monday, 16'th Oct 2023
NanoViricides (NYSE-A:NNVC) said it has sufficient funds to complete its ongoing Phase 1a/1b clinical trial of its lead drug candidate NV-CoV-2 based on its “nanoviricle” active pharmaceutical ing
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
06:45am, Thursday, 12'th Oct 2023
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at t
NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug
08:16am, Monday, 21'st Aug 2023
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collabor
NanoViricides creating special purpose nanomaterials for antiviral therapy
08:01am, Thursday, 13'th Jul 2023
As a war often accelerates technological innovation, the recent coronavirus pandemic in 2020 provided a big spur to advancements in biotechnology, with the rapid development of vaccines to contain the
NanoViricides reveals promising efficacy of its antiviral drug candidate in combating RSV
08:17am, Tuesday, 11'th Jul 2023
NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate NV-387 in combating Respiratory Syncytial Virus (RSV) infection in an animal model. NV-387, the ac
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
03:16pm, Thursday, 06'th Jul 2023 InvestorsHub
SHELTON, CO -- July 6, 2023 -- InvestorsHub NewsWire -- NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.
NanoViricides is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform. NV-CoV-2 (API NV-387), our lead drug candidate for the treatment of coronavirus infections including COVID and potent...
NanoViricides says clinical trial progressing satisfactorily for its broad-spectrum antiviral drug
08:03am, Thursday, 06'th Jul 2023
NanoViricides Inc (NYSE-A:NNVC) has announced that the clinical trial of its broad-spectrum antiviral drug, NV-CoV-2, is progressing satisfactorily. The drug is being developed as a potential treatmen